The Pharmaceutical Market: India

Publication Date	February 2008
Publisher	Espicom
Product Type	Report
Pages	212
ISBN Number	not applicable
Product Code	ESP00003

Price

£595.00
approximately: $1,169 | €756

PDF

PRINT £595 ($1,169 | €756)

Order above formats by FAX

Summary

India has a huge population in excess of one billion people. At current growth rates, it will reach around 1.2 billion by 2010, of whom around 58 million will be aged 65 years and over. As the country develops, India has a growing middle class population with access to high quality healthcare in some of the best private healthcare facilities in the world. Leading private healthcare providers are also striving to make India an international health resort, with an airport to airport concept of health tourism.

But, India is a country of extremes. The vast majority of the population is both rural and poor, although urban poverty is also a problem. Modern healthcare technology and western style pharmaceuticals are not even an issue for millions of people. On a national level, the Indian health system is ill-equipped to cope with the rising number of elderly and the changing disease patterns, with an average of just 0.7 hospital beds and 0.6 physicians per thousand population. India faces the continuing challenge of fighting infectious diseases like malaria, tuberculosis and leprosy alongside increases in lifestyle related problems faced by the developed world, such as cancer, cardiovascular disease and diabetes.

The introduction of product patents since 2005 has renewed multinational interest in India and there have been a number of acquisitions of Indian companies. Recently, for example, Solvay signed a binding sale and purchase agreement for the acquisition of the Polymers Division of Gharda Chemicals. But the news is not all bad for the domestic industry. Running parallel to the opportunities for foreign acquisition, however, are the opportunities that arise for domestic companies for collaboration with foreign companies interested in capitalising on India's renowned skills and relatively low costs.

India has more US FDA approved laboratories than any other country outside the USA. A number of US companies already source pharmaceutical raw materials from India. In comparison with China, the wide use of English in commerce is mooted as an advantage to US companies, along with India's tradition as an exporting nation. India should prove to be a useful regional production base. Partnering an Indian company may also provide a good route to commercialisation in targeted markets such as Brazil or Russia, where Indian companies have an established presence. In addition, India has a large and varied patient base along with the necessary chemical and analytical skills at a comparatively low cost to make it an attractive base for clinical trials. R&D alliances are already being forged between multinationals and domestic companies.

India accounts for less than two per cent of the world market for pharmaceuticals, with an estimated market value of US$11.3 billion in 2008 at consumer prices, or around US$10 per capita. The vast majority of pharmaceuticals available in India are already off patent and generics are likely to dominate the market for the foreseeable future.

Content

Background Data
- Geography
- Political Overview
- Economic Overview
- Population
  - Population by States and Territories, 2001-2007
- Demographic Indicators
  - Demographic Indicators, 1996-2006
  - Demographic Indicators by State, 2006
- Mortality
  - Medically Certified Deaths by Cause, 2000
  - Major Causes of Death, Rural India 1993-1998
  - Deaths from Non-Communicable Diseases, 1998
- Morbidity
  - National Rural Health Mission
  - Child Survival and Safe Motherhood
    - Reproductive and Child Health Programme
    - Universal Immunisation Programme
  - Reported Incidence of Vaccine Preventable Diseases, 1985-2006
    - Reducing Fertility
    - Family Planning
    - All India Hospitals Post-Partum Programme
  - National Health Programmes for Disease Control/Eradication
    - National Vector Borne Disease Control Programme
    - Malaria
  - Reported Malaria Incidence & Deaths, 1996-2006
    - Filariasis
    - Kala-azar
  - Reported Kala-azar Cases & Deaths, 1996-2006
    - Japanese Encephalitis
  - Suspected Japanese Encephalitis Cases & Deaths, 2000-2006
    - National Programme for the Control of Blindness
    - National Leprosy Eradication Programme
    - National Tuberculosis Control Programme
    - HIV/AIDS
    - National AIDS Control Programme
    - Cancer
  - Leading Cancer Sites in Males (HBCR), 2001-2003
  - Leading Cancer Sites in Females (HBCR), 2001-2003
- Charts
  - Map of India
  - Population by Age Group, 2006 (%)
  - Medically Certified Deaths by Cause, 2000
Healthcare System
- Organisation & Administration
  - Department of Health and Family Welfare
  - The Department of AYUSH
  - Health Insurance
  - Apollo Family Health Plan
- Health Expenditure
  - Health Expenditure by Source of Funds, 2001/02
  - Department of Health & Family Welfare: Health Sector Expenditure by Scheme, 2005/06
- Hospital Services
  - Hospital Resources
    - Hospitals & Beds by State & Sector, 2002
    - Government Hospitals/CHCs and Beds by State, 2007
    - Hospitals, Dispensaries & Beds, 1991-1998
    - Beds in Selected Hospitals, 2006
  - All India Institute of Medical Sciences (AIIMS)
    - AIIMS Hospital Beds, 2005/06
    - AIIMS Hospital Activity, 2005/06
    - AIIMS Inpatients by Specialty, 2005/06
  - Safdarjung Hospital, New Delhi
    - Safdarjung Hospital Beds by Specialty, 2003
  - Dr. Ram Manohar Lohia Hospital, New Delhi
    - Dr. Ram Manohar Lohia Hospital Beds by Specialty, 2000/01
  - JIPMER Hospital, Pondicherry
    - JIPMER Hospital Beds by Specialty, 2000
  - PGIMER Nehru Hospital, Chandigarh
    - PGIMER Nehru Hospital Beds by Specialty, 2004/05
  - Lady Hardinge Medical College Associated Hospitals, New Delhi
  - Private Hospitals and Clinics
  - Apollo Hospitals Group
  - Fortis Healthcare
  - Max Healthcare
  - Other Commercial Providers
- Ambulatory Care
  - Sub-centres and Primary Health Centres, 2004-2006
  - CGHS out-patient Facilities,
  - First Aid and Disaster Relief
  - St. John Ambulance
  - Indian Red Cross Society
  - Healthcare for the Underprivileged, Scheduled Castes and Scheduled Tribes
- Healthcare System
  - Healthcare Infrastructure in Tribal/Scheduled Caste Areas, 1995-2005
  - Medical Care for Remote & Marginalised Tribal & Nomadic Communities
- Medical Personnel
  - Doctors Registered with State Medical Councils, 1995-2005
  - Registered Dental Surgeons, 1995-2005
  - Registered Nursing Personnel, 1995-2005
  - Healthcare Personnel in Rural Areas, 1998-2006
- Charts
Accessing The Pharmaceutical Market
- Introduction
- Regulatory Environment
  - National Pharmaceuticals Policy 2006
  - Pharmaceutical Registration
  - Advertising
  - Patent Protection & Intellectual Property Rights
    - Background to Pharmaceutical Patents
    - The Patents (Amendments) Bill, 2005
      - Compulsory Licensing
      - Pre- & Post-Grant Opposition
      - Mailbox Applications
      - Other Issues
    - The Patents (Amendment) Rules 2006
    - Previous Patents Act Amendments and Exclusive Marketing Rights
      - Glivec/Gleevec Patent Setback for Novartis
  - Pricing
    - Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
    - Drug Price Control Review Committee
- Distribution Channels
  - Medical Stores Organisation
- Trade Fairs
  - Biotech India 2007
  - India Chem 2008
  - Pharma Bio World Expo 2009
- Domestic Production
  - Global Sales by Leading Domestic Companies, 12 months ended
  - BCG Vaccine Laboratory, Chennai
  - Trade Associations
  - Domestic Producers
    - Alembic Ltd
    - Alembic: Manufacturing Facilities
    - Alembic Financial Results, 2003-2007
    - Aurobindo Pharma
    - Aurobindo Pharma: Manufacturing Facilities
    - Aurobindo Pharma: ANDA Approvals, 2004-2008
    - Cephazone Pharma: FDA ANDA Approval, 2007
    - Aurobindo Pharma: Financial Results, 2003-2007
    - Biocon
    - Biocon Financial Results, 2003-2007
    - Blue Cross Laboratories Ltd
    - Cipla Ltd
    - Cipla: Manufacturing Facilities
    - Cipla: FDA ANDA Approvals, 2007
    - Cipla: Tentative FDA ANDA Approvals
    - Cipla: Tentative FDA NDA Approvals
    - Cipla: Financial Results, 2003-2007
    - Dr. Reddy?s Laboratories Ltd
    - Dr. Reddy?s: Manufacturing Facilities
    - Dr. Reddy?s: FDA ANDA Approvals, 2002-2008
    - Dr. Reddy?s: Financial Summary, 2003-2007
    - Glenmark Pharmaceuticals
    - Glenmark: Manufacturing Facilities
    - Glenmark: FDA ANDA Approvals, 2006-2007
    - Glenmark: Financial Results, 2003-2007
    - Lupin Limited
    - Lupin: Manufacturing Facilities
    - Lupin: FDA ANDA Approvals 2003-2008
    - Lupin: Tentative FDA Approvals
    - Lupin: Financial Results, 2003-2007
    - Matrix Laboratories
    - Matrix: Manufacturing Facilities
    - Matrix FDA ANDA Approval, 2008
    - Matrix: Tentative FDA ANDA Approvals
    - Matrix: Financial Results, 2003-2007
    - Natco Pharma
    - Natco Pharma Financial Results, 2003-2007
    - Nicholas Piramal India Ltd
    - NPIL: Manufacturing Facilities
    - NPIL: Financial Results, 2003-2007
    - Orchid Chemicals & Pharmaceuticals Ltd
    - Orchid: Manufacturing Facilities
    - Orchid?s Top-10 Brands
    - Orchid: FDA ANDA Approvals, 2005-2008
    - Orchid: Financial Results, 2003-2007
    - Ranbaxy Laboratories Ltd
    - Ranbaxy: Manufacturing Facilities
    - Ranbaxy Laboratories: FDA ANDA Approvals, 2002-2007
    - Ohm Laboratories: FDA ANDA Approvals, 2006-2007
    - Ranbaxy Financial Results, 2003-2007
    - Sun Pharma
    - Sun Pharma: Manufacturing Facilities
    - Sun Pharma: FDA ANDA Approvals, 2006-2007
    - Caraco Pharmaceutical: ANDA Approvals, 2002-2008
    - Sun Pharma: Financial Results, 2003-2007
    - Wockhardt Ltd
    - Wockhardt Manufacturing Facilities
    - Wockhardt: FDA ANDA Approvals, 2003-2008
    - Wockhardt: Financial Results, 2003-2006
    - Zydus Cadila
    - Zydus Cadila: Manufacturing Facilities
    - Zydus: ANDA Approvals, 2005-2008
    - Zydus Cadila: Consolidated Results, 2006-2007
    - Cadila Healthcare: Financial Results, 2003-2007
    - Zydus Cadila: Domestic Formulations Sales by Therapy Area, 2006
    - Multinational Activity
    - Actavis
    - GlaxoSmithKline
    - Pfizer India
    - sanofi-aventis
  - Research & Development
    - New Millennium Indian Technology Leadership Initiative
    - Indian Council of Medical Research
    - Central Research Institute, Kasauli
    - Central Drug Research Institute, Lucknow
    - Central Council for Research in Unani Medicine
    - Central Council for Research in Ayurveda and Siddha
    - Central Council for Research in Homeopathy
  - Traditional Indian Medicines
    - Components
    - Ayurvedic Supply
- Directory
  - Government Organisations
  - Trade Associations
- Charts
  - Cipla: Exports by Region, 2007 (%)
  - Dr. Reddy's: Sales by Region, 2007 (%)
  - Glenmark: Formulations Sales by Region, 2007 (%)
  - Matrix: Sales by Region, 2006 (%)
  - Orchid: API Sales by Region, 2007 (%)
  - Orchid: Formulations Sales by Region, 2007 (%)
  - Wockhardt: Sales by Region, 2006 (%)
  - Zydus Cadila: Sales by Region, 2007 (%)